Gujarat Themis Biosyn has initiated a postal ballot to seek shareholder approval for raising up to ₹1,000 crore through a Qualified Institutions Placement (QIP), aiming to fund growth opportunities and repay existing borrowings. The remote e-voting process, managed by Central Depository Services (India) Limited (CDSL), commenced on July 24, 2026, at 9:00 a.m. (IST) and concludes on August 22, 2026, at 5:00 p.m. (IST). Shareholders holding equity as of the July 17, 2026 cut-off date are eligible to vote on this resolution, alongside two other special resolutions concerning debt issuance and corporate governance amendments.

The QIP proposal supersedes a previous resolution passed by members on July 8, 2026, granting the Board broader discretion to issue equity shares or convertible securities to eligible qualified institutional buyers (QIBs). Under the terms of the resolution, no single allottee can receive more than 50% of the issue size, and a minimum of 10% of the securities must be allotted to mutual funds. The issued securities will carry a one-year lock-in period from the date of allotment. Additionally, the Board is authorized to offer a discount of up to 5% on the floor price determined under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR Regulations).

The second special resolution seeks approval for the private placement of non-convertible debentures (NCDs) and other debt securities, with an outstanding principal amount not exceeding ₹1,500 crore. This authorization allows the Board to diversify the company’s debt portfolio and access competitive borrowing sources. The Board retains the authority to determine the terms, pricing, interest rates, and security structures of these instruments based on prevailing market conditions. These debt securities may be listed on recognized stock exchanges as per statutory provisions.

The third resolution proposes an amendment to Article 13(1)(c) of the Articles of Association. Currently, the Articles require that the price of further share issues be determined by a registered valuer who submits a valuation report. The proposed amendment removes this unconditional requirement, aligning the company’s internal governance documents with the prevailing legal framework under the Companies Act, 2013 and SEBI regulations. This change ensures that valuation reports are obtained only when explicitly mandated by law, preventing unnecessary restrictions on capital raising activities.

Proceeds from the QIP will be utilized for prepayment of existing borrowings, investments in subsidiaries, capital expenditure, working capital, and inorganic growth through acquisitions. Not more than 25% of the net proceeds can be used for general corporate purposes. A monitoring agency registered with SEBI will track the utilization of proceeds if the issue size exceeds ₹100 crore, submitting quarterly reports until full deployment. The Board has confirmed that no directors, promoters, or key managerial personnel intend to subscribe to the QIP, and there will be no change in control or management of the company consequent to the issue.

What the Numbers Show

The dual-track fundraising strategy—combining a ₹1,000 crore equity mandate with a ₹1,500 crore debt facility—signals a significant push for balance sheet optimization and expansion. By securing upfront shareholder approval for both instruments, Gujarat Themis Biosyn positions itself to act swiftly on market opportunities without seeking repeated approvals. The restriction limiting general corporate purpose usage to 25% of QIP proceeds indicates a focused deployment strategy, prioritizing debt reduction and specific growth initiatives over unrestricted cash accumulation.

Promoters of Themis Medicare Limited and its subsidiary Gujarat Themis Biosyn Limited released pledged shares totaling 56,95,000 equity shares in July 2026. The releases were driven by the repayment of loans, significantly reducing the encumbrance on the promoter group's shareholding. Disclosures were submitted to BSE Limited and National Stock Exchange of India Limited on July 16 and July 20, 2026, in compliance with Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Release of Pledges by Themis Medicare Promoter

Vividhmargi Investments Private Limited, a promoter of Themis Medicare Limited, released pledges over 15,00,000 equity shares on July 8, 2026. The release was executed in favour of Bajaj Finance Limited. Prior to this transaction, the entity held encumbered shares representing 1.63% of the total share capital. Following the release, the remaining encumbered holding stands at NIL.

Release of Pledges by Gujarat Themis Biosyn Promoters

Promoter group entities of Gujarat Themis Biosyn Limited, Themis Medicare Limited and Pharmaceutical Business Group (India) Limited, released pledges over 41,95,000 equity shares on July 8, 2026. The release was executed in favour of Jio Credit Limited and Bajaj Finance Limited. Prior to these transactions, the promoter group held encumbered shares representing 3.85% of the total share capital. Following the release, the remaining encumbered holding stands at 5,000 shares, which constitutes 0.004% of the total equity share capital.

Shareholding and Encumbrance Status

The tables below detail the promoters' shareholding and the status of the encumbrance post the release events: